High Point Advisor Group LLC Autolus Therapeutics PLC Transaction History
High Point Advisor Group LLC
- $1.84 Billion
- Q2 2025
A detailed history of High Point Advisor Group LLC transactions in Autolus Therapeutics PLC stock. As of the latest transaction made, High Point Advisor Group LLC holds 108,620 shares of AUTL stock, worth $184,654. This represents 0.01% of its overall portfolio holdings.
Number of Shares
108,620
Previous 79,120
37.29%
Holding current value
$184,654
Previous $122,000
102.46%
% of portfolio
0.01%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding AUTL
# of Institutions
100Shares Held
164MCall Options Held
0Put Options Held
39.3K-
Wellington Management Group LLP Boston, MA27.1MShares$46.1 Million0.01% of portfolio
-
Blackstone Inc New York, NY20.5MShares$34.8 Million0.22% of portfolio
-
Mak Capital One LLC New York, NY17MShares$28.8 Million5.54% of portfolio
-
Deep Track Capital, LP Greenwich, CT16.9MShares$28.6 Million1.36% of portfolio
-
Syncona Portfolio LTD Guernsey, Channel Islands, X016.6MShares$28.3 Million98.24% of portfolio
About Autolus Therapeutics plc
- Ticker AUTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 90,909,800
- Market Cap $155M
- Description
- Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company's clinical-stage programs include obecabtagene autoleucel (AUTO1), a CD19-targeting programmed T cell investigational therapy that is in Phase 1b/2 clinical trial for the treatment of adult ALL; AUTO1/22, which...